SimpleScreen CRC is a prescription only noninvasive blood test. It works by detecting signals associated with colorectal cancer through a standard blood draw that can be collected at any routine patient visit.

SimpleScreen CRC has limited detection of precancer and stage 1 colorectal cancer. The American Cancer Society guideline advises that blood-based tests should only be recommended to individuals who decline or have not completed one of the preferred colorectal cancer screening tests.¹ No bowel preparation or dietary restrictions are required.

¹American Cancer Society Guideline for Colorectal Cancer Screening. Updated May 27, 2026. Accessed September 2, 2026. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html.

No, Cologuard Plus is a noninvasive, stool-based screening test. SimpleScreen CRC is a blood-based screening test. Both are intended for adults 45 and older at average risk for colon cancer, but they are different tests.

SimpleScreen CRC is a noninvasive option for people who:

• Are 45 years old or older
• Have an average risk for colon cancer
• Have declined or did not complete an American Cancer Society preferred colon cancer screening method, such as a stool-based test or a colonoscopy

Talk to your doctor about other noninvasive screening options, like the Cologuard Plus test, to see which one works best for your needs and lifestyle.

Request a SimpleScreen CRC blood test from your doctor at your next checkup. They can order one for you and help schedule your blood draw. If they can’t perform it onsite, we can ship a kit to you. Take it to a local lab or use during a scheduled home visit with a mobile phlebotomist. Please keep the kit unopened until your appointment. You’ll receive your test result in about 2 weeks. Use our discussion guide to start a conversation with your doctor. 

Doctor discussion guide

SimpleScreen CRC tests your blood for cancer signals, with results that have shown:

• 81% cancer detection: Flags 81 out of 100 colorectal cancers, helping with detection and treatment.¹
• 90% specificity: Yields a negative result for 9 out of 10 people who don't have cancer or advanced precancerous lesions.¹

Although blood tests can be a helpful way to screen for colon cancer, the American Cancer Society’s guideline  directly states: 

"Blood-based screening tests are not preferred screening options at this time. You should only use a blood-based test if you’re not willing to get a stool-based test or a visual exam. You’ll need to get a follow-up colonoscopy if the blood-based test is positive. These tests aren’t as good at detecting precancerous growths, which may limit their potential to prevent colorectal cancer.” ¹

Doctor discussion guide

¹ACS. Guideline for Colorectal Cancer Screening. Updated May 27, 2026. Accessed September 2, 2026. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html.

Based on data from clinical studies, SimpleScreen CRC has limited detection of stage 1 (57%) colorectal cancer (64% when U.S. 2020 Census age-sex adjusted) and does not detect 87% of advanced precancerous lesions (86% when U.S. 2020 Census age-sex adjusted).¹

1 out of 10 patients with a negative SimpleScreen CRC result may have a precancer that would have been detected by a colonoscopy.¹

¹SimpleScreen CRC Provider Brochure. Freenome LLC. Brisbane, CA

No, a blood test does not replace a diagnostic or surveillance colonoscopy for people at higher risk. A positive SimpleScreen CRC result should be followed by a colonoscopy.

SimpleScreen CRC is NOT indicated for use for patients that have the following:

• A personal history of colorectal cancer (CRC), advanced precancerous lesions (APLs), or other related cancers
• A family history of CRC, defined as having one or more first-degree relatives (parent, sibling, or child) diagnosed with CRC at any age
• A positive result on another CRC screening method within the last six months, or:
• A fecal occult blood test (FOBT) or fecal immunochemical test (FIT) within the last 12 months
• A FIT-DNA test within the last 36 months
• Personal history of any of the following high-risk conditions for CRC:
• Inflammatory bowel disease (IBD), including chronic ulcerative colitis (CUC) and Crohn’s disease
• Relevant hereditary cancer syndromes including but not limited to: hereditary non- polyposis colorectal cancer syndrome (HNPCC) or Lynch syndrome, familial adenomatous polyposis (FAP or Gardner’s), Familial Hyperplastic Polyposis, Peutz-Jeghers syndrome, MUTYH-associated polyposis (MAP), Cowden’s syndrome, Juvenile polyposis syndrome, serrated polyposis syndrome, and Turcot’s/Crail’s syndrome, Cronkhite-Canada syndrome, or Neurofibromatosis

SimpleScreen CRC is covered for Medicare Part B and MedAdvantage plans. Possible out-of-pocket costs may occur, so please check with your insurance provider.

The SimpleScreen CRC test is developed and manufactured by Freenome, LLC.

If you receive both a Cologuard Plus and a SimpleScreen CRC test, you can choose either one of them to screen for colon cancer. If you’re not sure, don’t worry. A member of our Customer Care team will get in touch to guide you through the process.

For SimpleScreen CRC, a phlebotomist will need to visit your home and perform a blood draw. Please do not open your kit before your appointment. The Cologuard Plus test is a use-at-home collection kit that’s ready out of the box. Please follow the included instructions and make sure to send back your stool sample to the lab within the same, or next day at the latest. You can call us +1 844-870-8870 for further support.